- Motif Bio said it had presented findings from a trail of a treatment for bacterial skin infections at a conference in Atlanta.

Data from two Phase 3 trials of the investigational drug candidate iclaprim were presented at the American Society of Microbiology Microbe 2018 meeting.

The pooled data demonstrated that iclaprim was non-inferior to standard-of-care vancomycin and was well tolerated in the patient population, the company said.

At 9:15am: [LON:MTFB] Motif Bio Plc Ord 1p share price was +0.28p at 32.28p

Story provided by